Had a great last day at #TLM2025 with inspiration and food for 🤔 👀 all 7 women @aasldnews.bsky.social presidents in one room (‼️) for the Women’s Luncheon 🔥🔥🔥discussion by @LaurenFeldMD and division chiefs on recruitment & retention of women hepatologists #liversky

Next gen hepatology Session by communication and technology committee All brilliant speakers! Proud to have served as the chair of this committee @aasldnews.bsky.social #TLM25 #liversky @howardtleemd.bsky.social

📣 NEW 💫 class of @aasldnews.bsky.social Women’s Leadership Development program mentees & mentors It was lovely to celebrate you with an inspiring keynote talk from #AASLD25 President Dr. Grace Su Looking forward to the year ahead! #TLM2025 #liversky #gisky

➡️What happens when you increase salary transparency? ➡️What is on a chief’s 🧠when negotiating a new hire? ➡️How to ⚖️ accommodations & consistency? Find out in our 🔥🔥 #TLM2025 panel @aasldnews.bsky.social #liversky @ast-whcop.bsky.social @ast-licop.bsky.social

Best practices of management of obesity in liver transplant FANTASTIC work by @drjessicadavis.bsky.social et al leading a controversy conference and consensus paper 👇🏼👇🏼👇🏼 Her beautiful graph won the cover photo 👌🏼 #liversky #TLM25 @aasldnews.bsky.social @ast-licop.bsky.social

Great practical talk by @dougsimonetto.bsky.social #TLM25 #liversky

Recompensation take home points ⏳off all diuretics and medications for HE 📌happens in 1 out of 3 patients depending etiology 🖋️multiple factors affect it 🔎 improves survival and LR mortality 📍Risk of HCC remains the same: don’t stop screening @anahitarabiee.bsky.social #liversky #TLM25

😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!) 🤝Well-aligned with @easlnews.bsky.social CPGs 😟Reimbursement currently restricted to semaglutide for T2DM 🤔Reimbursement in your country? 🖇️: rdcu.be/eLAde #LiverSky @georg-semmler.bsky.social

VA hepatitis C team winning the distinguished advocacy award. Truly well deserved 👏🏼 #liversky #TLM25

Kicking off the meeting with some of my favorite people #TLM25 #liversky

BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update If you take care of patients with #HCC, do not miss this new update from BCLC #liversky @easlnews.bsky.social www.journal-of-hepatology.eu/article/S016....

In anticipation of registration for @bavenocoop.bsky.social VIII Do not miss this new publication on refining Baveno VII criteria for CSPH individual-patient data meta-analysis #liversky pubmed.ncbi.nlm.nih.gov/41138818/ @easlnews.bsky.social

Once bleeding is controlled with banding: Can duration of octreotide infusion be shortened? In this RCT, 1 v 5 days of Oct infusion post successful EVL was non inferior in prevention of bleeding and all-cause mortality #liversky @amcollegegastro.bsky.social pubmed.ncbi.nlm.nih.gov/41090987/

📌A dual burden HCC risk is increased in MetALD compared to MASLD In a large cohort of VA patients, HCC risk MASLD>>MetALD>>ALD #liversky @easlnews.bsky.social www.sciencedirect.com/science/arti...

Anecdotally, I have noticed this in my patients. Great to see a publication supporting this. Meta-Analysis of irAE using ICI in HCC irAEs correlated with superior PFS & OS specially derm, endocrine & low-grade events #liversky onlinelibrary.wiley.com/doi/10.1111/...

📌 AGA clinical practice update on ascites and hyponatremia @amergastroassn.bsky.social #liversky www.gastrojournal.org/article/S001...

⏳ Just 5 months left for #BavenoVIII! 🗓️ 27-28 March 2026 (👶 Pediatric Symposium: 29 March) 📍 Baveno, Italy 🌐 The event will take place in a hybrid formula — both in person and online. 🧠 Call for abstracts is now open! 🔗 More info at: baveno8.org 🧵

➡️What #livertransplant candidates should get #GLP1-RA? ➡️Best timing for #bariatricsurgery in transplant? ➡️Data for #GLP1-RA in #cirrhosis? 🚨check out our @amjtransplant.bsky.social best practices for #obesity & liver transplant 👇 doi.org/10.1016/j.aj... #liversky #GIsky #transplant

Changes in trend and comparison of outcomes of TACE vs TARE as bridge therapy for patients with HCC on LT list #liversky @aasldnews.bsky.social

Important study on use of ICI post-transplant Only one rejection! #liversky @aasldnews.bsky.social journals.lww.com/lt/abstract/...

Ever wonder what happens to your liver after binge drinking? This study showed 📌increased hepatic fat fraction by 2.5-fold in healthy adults 📌increased liver stiffness 📌increased plasma triglycerides Good news: All normalized with 10 days of abstinence #liversky www.jhep-reports.eu/cms/10.1016/...

Optimal sequencing post immunotherapy for HCC as first line A good overview #liversky @easlnews.bsky.social www.jhep-reports.eu/article/S258...

Eye opening statistics re: HCC surveillance and how underutilized the guidelines are any HCC surveillance a little over 50% biannual surveillance 10% #liversky onlinelibrary.wiley.com/doi/epdf/10....

RCT comparing TJ liver biopsy and HVPG vs EUS LB and PPG measurement Would LOVE to hear @juanc60.bsky.social and @virginiahdezgea.bsky.social editorial on this paper #liversky @amergastroassn.bsky.social www.cghjournal.org/article/S154...

Comprehensive review on evolution of immunotherapy for HCC #liversky #HCC @aasldnews.bsky.social journals.lww.com/hep/abstract...

A great review on a not so common liver disease "Sarcoid in liver" #liversky @aasldnews.bsky.social journals.lww.com/hep/abstract...

HES V2.0 biomarker panel (AFP, AFP-L3, and DCP, their gradient, if available), ALT, platelets, etiology showed higher sensitivity than GALAD at 12 months for HCC diagnosis #liversky @jhepatology.bsky.social www.journal-of-hepatology.eu/article/S016...

If you are in the field of liver transplant, do not miss the 1st successful porcine liver xenotransplantation to a living recipient Postoperative xTMA -> significant challenge to long-term success #Liversky @jhepatology.bsky.social www.journal-of-hepatology.eu/article/S016...

Beautiful study looking at effects of early PoPH on mortality in patients with cirrhosis #liversky @jhepatology.bsky.social www.journal-of-hepatology.eu/article/S016...

Great review of reproductive health in the liver transplant recipient by Dr Sarkar et al journals.lww.com/lt/abstract/... #liversky

Multinational real-world data supports lenvatinib as preferred second-line option in HCC treatment 👇🏼👇🏼👇🏼 www.jhep-reports.eu/article/S258... #liversky @easlnews.bsky.social

If you are interested in portal hypertension and like to hear from all disciplines involved, this is the conference for you 👇🏼 Thank you for the invitation and the opportunity to review HRS-AKI and ascites management. #liversky @portal360mtg.bsky.social @bavenocoop.bsky.social

In this study on reactivation of hepatitis B in patients with HCC ✅ Overall risk of HBV reactivation is low ✅ Risk is no affected by the choice of TKI or different types of ICI #Liversky onlinelibrary.wiley.com/doi/full/10....

AlcHepNet consortium puts the focus on early intervention 712 AH patients Composite event 64% Liver transplant 12% Mortality in severe AH 17% (30d), 26% (90d), 30% (180d) Higher mortality: High MELD score Low MAP Leukocytosis #liversky @aasldnews.bsky.social journals.lww.com/hep/abstract...

Save and keep it handy for when you are asked to “clear” patients with cirrhosis. Or as I prefer to say it “have a risk, benefit discussion before surgical procedures” There is also a visual highlight 🤩 journals.lww.com/ajg/fulltext... @amcollegegastro.bsky.social #liversky

Updated Liver Transplant Guidelines from @aasldnews.bsky.social journals.lww.com/lt/abstract/... @livertransplant.bsky.social #Liversky

A very comprehensive review on current state of HCC screening, diagnosis and treatment. www.jhep-reports.eu/article/S258... #Liversky @easlnews.bsky.social

handy easy to read paper on Guidance for Timely Referral to Liver Transplantation www.cghjournal.org/action/showP... #liversky @ast-licop.bsky.social

HE post TIPS - elective vs preemptive - different prevalence - different risk factors - different outcomes #liversky www.jhep-reports.eu/article/S258... @easlnews.bsky.social

One approach to individualize approach to volume rescuscitation is to use POC US See this wonderful study addressing this 👇 www.jhep-reports.eu/article/S258... #liversky @easlnews.bsky.social

A refresher on less common hepatitis: HDV AGA Clinical Practice Update on Management of Hepatitis Delta More and more advocate for universal testing in those with hepatitis B. #liversky www.gastrojournal.org/action/showP... @amergastroassn.bsky.social

24 hour vs 48 hour for initial volume expansion and diagnosis of AKI-HRS? The debate continues... We can all agree that it should be individualized. #liversky www.journal-of-hepatology.eu/article/S016... www.journal-of-hepatology.eu/article/S016... @jhepatology.bsky.social

In today’s #readoftheweek📚, the authors explore how TIPS could limit the risk of portal hypertensive complications in patients with ascites. Read here this JHEP Reports article: www.jhep-reports.eu/article/S258... #LiverSky

In this interesting study They evaluated the hazards of ⬆️ distance from LT center on waitlist mortality and receipt of LT 📍No impact on LT waitlist mortality or receipt of LT. 📍Only differences in healthcare utilization in pre-LT #liversky journals.lww.com/ajg/abstract...

A new but tested and tried mentorship method 👇🏼 Near-Peer mentorship 😊 @drjessicadavis.bsky.social Thank you for spearheading the project #liversky journals.lww.com/lt/abstract/...

Thanks to our team at the VA and Georgetown, thanks to @drjessicadavis.bsky.social for spearheading the publication and most importantly thanks to our patients trusting us with their care. Very proud 😊

2 🐥🐥 1 🪨 In this VA study, GLP-1 RA use was a/w a 📉 risk of liver outcomes, death, & harmful alcohol use #Liversky journals.lww.com/ajg/abstract... @amcollegegastro.bsky.social

Congrats! What an accomplishment! So proud of you 😊

🚨 #LiverSky interested in #Cirrhosis and #PortalHypertension ➡️ Read the #Baveno VII Consensus 🔗 t.ly/1P7Ta Get Ready and Register for the #Baveno VIII Consensus 📆 27-28 MARCH 2026 🔗 baveno8.org @bavenocoop.bsky.social @easlnews.bsky.social @aasldnews.bsky.social

Among patients with previously untreated advanced HCC, the anti-PD-1 antibody toripalimab plus bevacizumab resulted in significantly longer PFS & OS than did sorafenib, with acceptable safety. The regimen has been approved for use in China. #oncsky #liversky #medsky @oncoalert.bsky.social